NEW YORK (GenomeWeb News) – A non-profit organization called the National Biomarker Development Alliance has launched to develop standards and guidelines for supporting biomarker development and use, the NBDA said today.

The NBDA was created to "address the complex and urgent challenge of creating the standards to support end-to-end evidence-based biomarker development," and will engage partners from industry, academia, government, and patient groups, NBDA said.

The alliance was established and launched today by the Research Collaboratory at Arizona State University

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.